
PL BioScience appoints Oliver Dick as chief technology officer
Ella Day | June 12, 2025 | Appointment | Clinical trials supplies & documentation logistics, Manufacturing and Production, Research and Development | Corporate, Devices, Human Platelet Lysate, PL Bioscience, animal-free cell culture, life sciences
PL BioScience, a German life sciences company specialising in the production and development of human platelet lysate (HPL) for cell expansion, has announced the strengthening of its management team with the appointment of Oliver Dick as chief technology officer. This intends to support HPL upscaling in alignment with growing global demand for its animal-free cell culture solutions.
Dick is an experienced operations executive with over 30 years of experience in project and line management, specialising in process optimisation, cost reduction and digital transformation. Prior to joining PL BioScience, he was an operations consultant at ODICON and chief operating officer at both Resolve BioSciences and Miltenyi Biotec. Additionally, he held a number of senior leadership roles at QIAGEN and Pharmaplan.
“Oliver has an extensive track record in operational excellence and brings a strategic vision as well as hands-on leadership to our team,” said Hatim Hemeda, CEO of PL BioScience. “We are delighted to have him as we enter into this exciting phase.”
HPL is a human-derived cell culture supplement used to support the growth and expansion of cells in clinical research, especially in cell therapy, stem cell and regenerative medicine applications.
“The company is in an excellent position to shape the market globally. I look forward to working with the team,” commented Dick.
Ella Day
12/6/25
Related Content

Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Crown Bioscience opens new US model development centre
Crown Bioscience, a US global contract research organisation (CRO) that is part of JSR Life …






